CLOV Q2 2026 - Post-Call Earnings Update

Event: Quartr Q2 2026 event Retrieved: 2026-08-06T00:22:00Z Comparison mode: maximal Scorecard contract: v1

Consensus scorecard

Management and Q&A

Prepared remarks — CEO Andrew Toy:

• Framed the thesis around Clover Assistant: "the greatest opportunity for AI in healthcare is not simply to make the existing system a little more efficient. It's to help physicians make better decisions for individual patients at the point of care."
• First-half results cited as proof: Medicare Advantage membership growth of 48%, GAAP net income up $67 million year over year, total revenue up more than $550 million to $1.5 billion, consolidated gross profit up $104 million, and operating leverage expanded by more than 200 basis points.
• Named two developments strengthening confidence in 2027: the star rating recalculation and continued cohort maturation, and insisted on separating them — "the higher star rating gives us more flexibility. Cohort maturation is what strengthens the underlying earnings engine."
• Star rating: following the court's order and CMS's recalculation, all Medicare Advantage members are now enrolled in plans rated four and a half stars for payment year 2027. CMS has filed notice of intent to appeal; Toy said the District Court ruling "was thorough and well-reasoned, and we are prepared to defend it on appeal," and kept remarks brief because the matter is pending litigation.
• Said the rating "gives us more room to reinvest in members, maintain a highly competitive product, support growth, and expand profitability. It does not create the economics of our model."
• Described the model as a wide network, full risk PPO built so that "seniors should be able to get an affordable product without being forced to give up broad physician choice," with Clover Assistant solving the underlying clinical decision problem. Cited Clover as the top-rated HEDIS PPO plan in the country.
• On geography: the four and a half star rating strengthens the product particularly across core New Jersey and Georgia markets, and "we do not feel compelled to [expand to more geographies] just to chase a top-line growth number."
• Cohort economics: "we've shared before that our cohorts typically improve by about $70 PMPM in gross profit as they move from year one to year two," and said that progression is playing out this year in the large 2025 cohort. By 2027 that cohort will be in year three and the 2026 cohort in year two.
• Closed by announcing the company is "now moving quickly to bring AI into our back office insurance operations themselves," to improve claims processing speed and accuracy and "completely change the way we scale the business with regard to admin expense."

Prepared remarks — Interim CFO Clay Thornton:

• Q2: Medicare Advantage membership up 48% year over year, $41 million of adjusted EBITDA and $28 million of GAAP net income.
• Average Medicare Advantage membership of 157,000, driving total revenue of $743 million, up 56% year over year, with growth "disciplined and concentrated" in New Jersey and Georgia.
• Consolidated gross profit of $153 million, up 54% year over year, supported by favorable trend development and cohort progression.
• Medical cost trends: inpatient utilization continues to trend favorably overall, "including among our year one members, where utilization is tracking below the comparable new member cohort from a year ago." Outpatient trends "peaked in March and have since moderated in Q2," remaining elevated versus prior years but within expectations.
• Dental cost performance continues to improve following changes to how out-of-network dental claims are managed. Part D has performed better than expected in the second year of IRA implementation, with stronger visibility into seasonality.
• Adjusted SG&A of $112 million, 15% of total revenue, an improvement of approximately 220 basis points versus Q2 2025, while continuing deliberate investment in Clover Assistant, Counterpart Health go-to-market, and health plan operations.
• First-half totals: $81 million of adjusted EBITDA and $55 million of GAAP net income. Ended the quarter with $443 million of cash and investments and no debt outstanding; first-half cash flow from operations of $133 million.
• Raised full-year guidance across all metrics, while calling it "a balanced outlook" and saying "it's prudent to allow additional claims experience to emerge before assuming current trends will persist through year-end."
• Second-half shape: consolidated gross profit stronger in Q3 than Q4 on typical Medicare Advantage seasonality; investments increasing in Q4 including AEP-related activities; adjusted EBITDA positive in Q3 "before returning to a more typical seasonal loss in the fourth quarter," with the second half still a significant improvement on last year.
• Listed five supporting indicators: high retention; more members under Clover Assistant-powered primary care with expanding Clover Care Services engagement; stable utilization trends performing better than original expectations; meaningful operating leverage as membership has nearly doubled since 2024; and 2025 and 2026 cohorts developing in line with or ahead of expectations.
• On 2027: "New members create expected near-term pressure because they are earlier in their Clover life cycle." The 2025 cohort created the expected first-year margin headwind last year and is now showing "meaningfully stronger economics" in year two; the 2026 cohort is following the same early pattern. Next year the 2025 cohort moves to year three "where our historical data shows another meaningful step-up in economics."
• Said the four and a half star payment year "does not change the underlying earnings trajectory we expected from cohort maturation. It simply provided additional flexibility as we finalized our 2027 bids," and that the ultimate benefit depends on final bid economics and 2027 enrollment, on which no detail was provided.
• Stated the near-term focus as "delivering our first full year of GAAP net income profitability and entering 2027 from a position of strength."

Question and answer:

• Richard Close (Canaccord Genuity) asked what share of the 2025 and 2026 cohorts is managed under Clover Assistant, against two-thirds across the overall population. Thornton said coverage in those cohorts is "in the low 60s," and that engagement "generally trends up over time" toward the two-thirds level as members stay longer.
• On cohort sizing for modeling 2026 into 2027, Thornton said the 2025 cohort represents about 21% of this year's membership and the 2026 cohort about 28%, and noted "a higher percentage of members will be shifting from year one to year two than year two to year three."
• On the sequential SG&A decline, Thornton said there was nothing particular in Q2; the first quarter had carried one-time non-recurring events, "for instance, the claims adjustment expense that we incurred in the first quarter when our IBNR reserves went up," and Q2 simply reflects their elimination.
• Jonathan Yong (UBS) asked how the 2027 bids were approached and what cost trend was assumed. Thornton said underlying cost trend assumptions are "generally not going to assume anything meaningfully different than the large national peers," and that what is distinctive for Clover is the value created by cohort maturation, which "becomes an offset to any near term margin headwind that you may face with bringing on additional year one members." He said the bids were approached "in a similar fashion that we have in the past two years," with the goal of a product the company knew it could grow profitably.
• Asked whether national carriers exiting markets was factored in, Thornton said "we definitely did assume continued disruption," citing significant disruption in New Jersey and Georgia in 2025 and 2026 and close attention to what nationals and local competitors signalled ahead of their bids.
• On star ratings performance, Toy said plan previews "are just about to come out," that Clover has been the number one PPO in the country on HEDIS star ratings for the last two years, and that the company is always investing in the other rating domains.
• Dean Rosales (Leerink, for Whit Mayo) asked about CAHPS in Plan Preview One. Thornton declined: "Plan Preview One is really just kicking off, so we're not going to comment specifically on any particular domain at this time," pointing to the October release of measurement year 2025 results.
• Asked whether the four and a half star benefit is assumed in the bids given the pending appeal, Toy said CMS has appealed and the company feels good about defending the ruling, but "just as a reminder for everyone, though, we are paid on 4.5 stars going into next year. We recalculated and we bid against that."

Guidance and KPI clarification

Updated neutral analysis

• The call did not change the quarter's scorecard: total revenues of $743 million beat consensus by 2.0% and GAAP diluted EPS of $0.05 beat by 29.5%. The call adds that Q2 carried $41 million of adjusted EBITDA and $28 million of GAAP net income on 48% membership growth.
• Full-year guidance was raised across all five metrics. The tension already visible in the release remains: guided full-year GAAP net income of $20-$35 million against $55 million earned in the first half implies a second-half GAAP net loss of $(35) million to $(20) million, and guided adjusted EBITDA of $70-$85 million against $81 million in the first half implies second-half adjusted EBITDA of $(11) million to $4 million. Management addressed this directly, attributing it to Medicare Advantage seasonality, Q4 investment including AEP, and a deliberate choice to "allow additional claims experience to emerge before assuming current trends will persist through year-end."
• The 2027 case rests on cohort maturation rather than the star rating, and management drew that line repeatedly and unprompted. The quantified anchor is approximately $70 PMPM of gross profit improvement from year one to year two, with a further step-up from year two to year three, applied to a 2025 cohort at approximately 21% of membership and a 2026 cohort at approximately 28% — roughly 49% of the base moving into more mature years.
• The star rating outcome is favorable but unsettled. All members are in four and a half star plans for payment year 2027, and 2027 bids were submitted against that rating, but CMS has filed notice of intent to appeal. Management framed the rating as flexibility in allocating value between member benefit, growth and margin rather than as an earnings driver, and declined to quantify the benefit, saying it depends on final bid economics and 2027 enrollment.
• Medical cost trend commentary was favorable but qualified. Inpatient is trending favorably including among year-one members; outpatient peaked in March and moderated but remains elevated versus prior years. Dental improvement is attributed to a specific operational change in out-of-network claims management, and Part D benefits from a second year of IRA visibility rather than from underlying cost performance.
• Operating leverage is real and quantified: adjusted SG&A at 15% of revenue, approximately 220 basis points better than a year ago, with membership nearly doubled since 2024. The Q2 sequential SG&A decline, however, is partly the absence of Q1 one-time items — management named a claims adjustment expense recorded when IBNR reserves rose — rather than incremental efficiency.
• Clover Assistant penetration in the newest cohorts is materially below the overall base: low 60s percent for the 2025 and 2026 cohorts against approximately two-thirds overall. Since the cohort economics thesis depends on Clover Assistant-driven care, the penetration gap in exactly the cohorts expected to drive 2027 is the operative execution question, and management's answer is that engagement rises with tenure.
• The 2027 bid posture assumes continued market disruption from national carriers exiting New Jersey and Georgia — the same dynamic management credits for 2025 and 2026 growth. Underlying cost trend assumptions are described as not meaningfully different from large national peers, so the differentiation claimed is entirely cohort maturation.
• Growth remains geographically concentrated by choice. Management said it will not expand markets "just to chase a top-line growth number," which limits the addressable base but keeps membership in markets where the care model is established.
• The balance sheet supports the plan without external funding: $443 million of cash and investments, no debt, and $133 million of first-half operating cash flow against a business management describes as able to self-fund future growth.
• A new margin lever was introduced without quantification: applying AI to back-office insurance operations to change administrative cost scaling. No target, timeline or expected saving was given.
• The chief financial officer is serving on an interim basis, and no permanent-appointment timeline was mentioned on the call.
• No formal 2027 guidance was given, and management declined to comment on Plan Preview One domain performance, deferring to the October release of measurement year 2025 results.

Market context and limitations

• API Ninjas snapshot: CLOV $4.14 on NASDAQ, volume 3,744,944, quote timestamped 2026-08-05T22:41:25Z, retrieved 2026-08-06T00:22:00Z. The release published after the U.S. close on 2026-08-05 and the call was held at 5:00 p.m. Eastern; this is a single quote of unstated session basis captured after the close, not a measured reaction to either the release or the call.
• The consensus scorecard is carried forward unchanged from the preliminary report for this event (reports/preliminary/2026-08-05-clov-q2-2026.md). No new actual in the call changes it: management stated total revenue of $743 million and GAAP net income of $28 million, consistent with the $743.167 million and $0.05 diluted EPS in the release.
• Every figure above comes from the Quartr transcript for event 661694, which is complete and not live. The full transcript was read.
• Figures management stated on the call are reproduced at the precision used on the call, which is generally rounded to whole millions and therefore differs slightly from the release's exact figures.
• Adjusted EBITDA, adjusted SG&A, consolidated gross profit, and operating leverage are non-GAAP or company-defined measures reconciled in the earnings materials rather than on the call.
• Prior-year Q2 total revenue of $476 million, consolidated gross profit of $99 million, adjusted SG&A ratio of 17.2%, first-half 2025 total revenue of approximately $0.95 billion, and first-half 2025 GAAP net loss of $(12) million are implied from the stated current values and the stated changes; management did not state them on the call.
• Prior FY2026 guidance ranges were not restated on the call, so the size of each raise cannot be quantified from this transcript.
• Implied second-half figures for total revenue, adjusted EBITDA and GAAP net income are calculated by subtracting the stated first-half actuals from the guided full-year ranges; management did not present them, though it did describe the expected seasonal shape.
• Full-year consolidated gross profit guidance of $525-$555 million cannot be split into halves because first-half consolidated gross profit was not stated in total on the call — only the $153 million second-quarter figure and the $104 million year-over-year first-half increase.
• The approximately $70 PMPM year-one to year-two gross profit improvement is a company-stated historical average that management says is illustrated in the supplemental presentation; that presentation was not read for this update.
• The star rating for payment year 2027 rests on a District Court decision that CMS has filed notice of intent to appeal; the outcome of that appeal is unresolved.
• Management declined to quantify the financial benefit of the four and a half star rating, to comment on Plan Preview One domain performance, or to provide 2027 guidance.
• The supplemental slides, investor deck and earnings materials furnished with the release were not read for this update.
• Cohort share percentages of approximately 21% and 28% are management's figures for this year's membership base and were given as modeling anchors, not as reported segment disclosure.

Source links

• Quartr Q2 2026 event overview
• Quartr Q2 2026 earnings call transcript
• Quartr Q2 2026 earnings release
• Preliminary report for this event